報價延遲最少15分鐘:2025/09/01 15:45 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6768 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.81/-0.09
|
|
企業價值
61.97M
|
| 資產負債 |
|
每股賬面淨值
-0.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/01 15:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |
